gip glp 1 agonist tirzepatide Understand GLP-1/GIP Dual and Its Effect on Current Weight Loss Therapy GLP-1/GIP dual agonist tirzepatide normalizes

Anemia: Causes, Symptoms, Diagnosis, Treatments

Statement development was guided by a systematic literature review and 12 global experts

Weight-loss drugs are changing how doctors treat obesity, but in South Africa the cost of approved medicines and the hype around new injections are fuelling a risky illegal market

If tirzepatide helped you lose weight at first but results have stalled, you're not alone

Between 2025 and 2030, the global pharmaceutical industry faces a Loss of Exclusivity (LOE) wave that puts an estimated $200 billion to $400 billion in branded drug revenue at direct risk.

*Only certain dosages are available in CA